Memory Pharmaceuticals' MEM 3454 found to be well tolerated, MEM 1003 trial to begin

By Lisa Kerner

Erie, Pa., April 25 - Memory Pharmaceuticals Corp. said its single ascending dose portion of the phase 1 clinical trial program showed MEM 3454 was safe and well-tolerated up to and including a dose of 450 mg. It was also safe and well-tolerated up to and including a dose of 150 mg in the multiple ascending dose portion of the program.

Memory plans to begin a phase 2a clinical trial of MEM 3454 in Alzheimer's disease in June.

The company said it also plans to start a phase 2a clinical trial of MEM 1003 in acute mania in bipolar disorder in the second quarter of this year, for completion in the first half of 2007.

The results on MEM 3454 and MEM 1003 were reported during the Research & Development Day in New York City, according to an 8-K filing with the Securities and Exchange Commission.

Memory is a Montvale, N.J. biopharmaceutical company developing drugs for central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.